Litcius/Paper detail

Identification of <scp>FDFT1</scp> as a potential biomarker associated with ferroptosis in <scp>ccRCC</scp>

Ruizhen Huang, Chiyu Zhang, Xing Wang, Xin Zou, Zhengjie Xiang, Zewei Wang, Bin Gui, Tao Lin, Honglin Hu

2022Cancer Medicine26 citationsDOIOpen Access PDF

Abstract

Renal cell carcinoma (RCC) seriously threatens people's lives and health. The identification of some precise biomarkers during the process of RCC progression and the pathophysiologic procedure is critical for improving the diagnosis and management of RCC. Evidence suggests that ferroptosis may play a pivotal role in eradicating clear cell RCC (ccRCC, KIRC) tumor cells. We screened out the target prognostic ferroptosis-associated genes and examined the functions of farnesyl-diphosphate farnesyltransferase (FDFT1) in 786-O cells by plasmid transfection. In our study, we identified FDFT1 as a potential marker correlating with ferroptosis in KIRC. Upregulated FDFT1 inhibited cell proliferation, migration, and invasion, and the underlying antitumor effects may occur via the AKT signaling pathway. Our study provides helpful evidence to study the complex physiopathology of KIRC.

Topics & Concepts

Clear cell renal cell carcinomaCancer researchBiomarkerIdentification (biology)BiologyFarnesyltransferaseProtein kinase BTransfectionCell growthSignal transductionRenal cell carcinomaGeneCell biologyMedicineInternal medicineGeneticsBiochemistryEnzymePrenylationBotanyFerroptosis and cancer prognosisCancer, Lipids, and MetabolismEpigenetics and DNA Methylation
Identification of <scp>FDFT1</scp> as a potential biomarker associated with ferroptosis in <scp>ccRCC</scp> | Litcius